Literature DB >> 12431693

Central serous chorioretinopathy and glucocorticoids.

Evrydiki A Bouzas1, Panagiotis Karadimas, Constantin J Pournaras.   

Abstract

Central serous chorioretinopathy is a relatively common retinal disease characterized by the accumulation of subretinal fluid at the posterior pole of the fundus, creating a circumscribed area of serous retinal detachment. It typically affects young and middle-aged men with no previous medical and family history, and no systemic symptoms or signs. However, it has been noted that central serous chorioretinopathy is associated with different conditions, characterized by exposure to increased levels of endogenous or exogenous glucocorticoids. In fact, central serous chorioretinopathy has been described in patients with endogenous Cushing's syndrome. It is also prevalent in patients with type-A behavior, and following stressful events, and pregnancy probably represents a risk factor for central serous chorioretinopathy; these conditions are characterized by endogenous hypercortisolism. In addition, many cases of central serous chorioretinopathy have been described during or following treatment with glucocorticoids, administrated by any route, for various systemic or ocular conditions. Central serous chorioretinopathy, when related to the exposure to exogenous glucocorticoids, has a less prominent male predilection, presents more often with a chronic or atypical form, and is frequently bilateral. Furthermore, treatment of central serous chorioretinopathy with glucocorticoids was found to exacerbate the clinical picture. Based on these observations it could be suggested that glucocorticoids may be involved in the development of central serous chorioretinopathy, even though the exact pathogenic mechanism remains unclear. Glucocorticoids should not be used in the treatment of central serous chorioretinopathy and central serous chorioretinopathy should be added to the list of ocular complications of glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431693     DOI: 10.1016/s0039-6257(02)00338-7

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  92 in total

1.  [Central serous chorioretinopathy (CSC)].

Authors:  H Baraki; N Feltgen; J Roider; H Hoerauf; C Klatt
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  Evaluation of Choroidal Thickness and Volume during the Third Trimester of Pregnancy using Enhanced Depth Imaging Optical Coherence Tomography: A Pilot Study.

Authors:  Renata T Rothwell; Dália M Meira; Marisa A Oliveira; Lígia F Ribeiro; Sofia L Fonseca
Journal:  J Clin Diagn Res       Date:  2015-08-01

3.  Hypercortisolism induced atypical central serous chorioretinopathy in pregnancy.

Authors:  Tarun Choudhary; Sushil Chawla; Rahul Ray; Savio Pereira
Journal:  Med J Armed Forces India       Date:  2013-04-18

4.  [Sudden unilateral loss of vision under high-dosage corticosteroid therapy for pansinusitis].

Authors:  F Alten; C H Meyer
Journal:  HNO       Date:  2011-05       Impact factor: 1.284

5.  Intravitreal triamcinolone acetonide and central serous chorioretinopathy.

Authors:  J B Jonas; B A Kamppeter
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

6.  Oral eplerenone for the management of chronic central serous chorioretinopathy.

Authors:  Rishi P Singh; Jonathan E Sears; Rumneek Bedi; Andrew P Schachat; Justis P Ehlers; Peter K Kaiser
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

7.  Response of central serous chorioretinopathy evaluated by multimodal retinal imaging.

Authors:  R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

8.  En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy.

Authors:  Daniela Ferrara; Kathrin J Mohler; Nadia Waheed; Mehreen Adhi; Jonathan J Liu; Ireneusz Grulkowski; Martin F Kraus; Caroline Baumal; Joachim Hornegger; James G Fujimoto; Jay S Duker
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

9.  Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.

Authors:  Francesco Pichi; Paola Carrai; Antonio Ciardella; Francine Behar-Cohen; Paolo Nucci
Journal:  Int Ophthalmol       Date:  2016-10-18       Impact factor: 2.031

10.  Viagra-associated serous macular detachment.

Authors:  Polly Quiram; Sean Dumars; Bobbie Parwar; David Sarraf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.